VANCOUVER, British Columbia, April 17, 2023 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/258,402…


Previous articleOpinions | The Church of Psilomethoxin: Fantasy Chemistry Gets Fact Checked
Next articleNuminus to Participate in a Water Tower Research Fireside Chat on Wednesday, April 19, 2023